Agomab Therapeutics, an Antwerp, Belgium-based biotech company developing novel treatments that aim to preserve and restore organ function in fibrotic diseases, raised $89M in Series D funding.
Backers included Sanofi and Invus.
Led by CEO Tim Knotnerus, Agomab is focused on achieving disease modification by modulating fibrosis and regeneration in chronic indications such as fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. It does this by targeting biologically validated pathways, including transforming growth factor β and hepatocyte growth factor, and by applying specialized capabilities in organ-restricted small molecules and high affinity antibodies.
The company intends to use the funds to further advance the ongoing clinical development of its lead candidate, AGMB-129, a gut-restricted oral small molecule inhibitor of ALK5 (TGFβ1R), in patients with fibrostenosing Crohn’s disease (FSCD).
FinSMEs
25/10/2024